Lilly's Foundayo Shows Modest Start vs. Novo's Wegovy

Foundayo's Second Week Shows Slow Uptake

Eli Lilly’s new oral weight-loss drug, Foundayo, recorded 3,707 prescriptions in the U.S. during its second week ending April 17. This figure represents a modest increase from the 1,390 prescriptions in its debut week, according to IQVIA data.

The initial numbers fall significantly short of the launch figures for Novo Nordisk's competing pill, Wegovy, which saw 18,410 prescriptions in its second week after launch.

Competitive Landscape in the Obesity Drug Market

The prescription data highlights the intense competition between Eli Lilly and Danish pharmaceutical giant Novo Nordisk in the lucrative oral obesity drug market. Investors are closely monitoring the rollout of Foundayo as a key indicator of Lilly's ability to capture market share from Novo Nordisk, which benefits from a first-mover advantage and established brand recognition with Wegovy.

Analysts note that the slower ramp-up for Foundayo was not entirely unexpected given Wegovy's established presence, though the initial uptake has been perceived negatively by the market.

Impact on Stock Performance and Analyst Views

Following the release of the prescription data, Eli Lilly's shares traded nearly 4% lower, while U.S.-listed shares of Novo Nordisk increased by approximately 6%. Wall Street analysts expressed concerns, with Deutsche Bank noting they would have preferred to see prescription numbers closer to 8,000.

RBC Capital Markets and Truist analysts also described the uptake as likely to be received negatively and modest, respectively. Lilly has cautioned that early weekly figures may not be fully comprehensive and should be interpreted over time.

Outlook and Future Monitoring

While the initial launch of Foundayo appears slower than its primary competitor, the long-term trajectory remains a key focus for investors. Future prescription data will be critical in determining whether Lilly can effectively challenge Novo Nordisk's dominance in the oral weight-loss treatment space. The company's own guidance suggests a fuller picture will emerge as distribution through retail pharmacies and telehealth providers expands.

FAQ

Q: How many prescriptions did Lilly's Foundayo achieve in its second week?
A: Foundayo was prescribed 3,707 times in its second week on the U.S. market.

Q: How does Foundayo's launch compare to Novo Nordisk's Wegovy?
A: Novo Nordisk's oral Wegovy achieved 18,410 prescriptions in its second week, significantly higher than Foundayo's 3,707.

Q: What was the immediate market reaction to this news?
A: Eli Lilly's stock price decreased by nearly 4%, whereas Novo Nordisk's stock price increased by about 6%.

Source: Investing.com